Azathioprine News and Research

RSS

Azathioprine is an immunosupressant used in organ transplantation, autoimmune disease such as rheumatoid arthritis or inflammatory bowel disease such as Crohn's disease and ulcerative colitis. It is a pro-drug, converted in the body to the active metabolites 6-mercaptopurine and 6-thioinosinic acid.

Immune responses to flu vaccine are diminished in lupus patients

Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs.

30 Jul 2009

Varicella zoster infection causes severe autoimmune hepatitis

Autoimmune hepatitis (AIH) is a chronic liver inflammation of unknown etiology that is characterized by the presence of circulatory autoantibodies and ongoing liver tissue damage.

2 Apr 2009

Emerging therapies could ease symptoms of Atopic dermatitis

Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children.

5 Mar 2009

Outlook for Crohn's disease improves due to new therapies

A study led by Mayo Clinic has found that infliximab (Remicade) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.

6 Oct 2008

Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with Methotrexate

A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer.

3 Jun 2008

Omega-3 fatty acids ineffective for managing Crohn's disease

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn's disease.

9 Apr 2008

Methods for treating lupus nephritis

Good patient information is essential for choosing the best treatment for the kidney disease lupus nephritis.

17 May 2007

Renal transplantation in 1-5 year olds

Garcia, et al reported their experience with renal transplantation in 38 children (40 transplant), ages 1-5 years over a 16 year period.

26 Apr 2007

Link between rheumatoid arthritis and cancer examined

Rheumatoid arthritis is an inflammatory disease of the immune system and is thought to be linked to an increased risk of cancers of the lymphatic system.

28 Feb 2006

Study associates chronic, severe inflammation with increased lymphoma risk among RA patients

An inflammatory disease of the immune system, rheumatoid arthritis (RA) is associated with increased occurrence of lymphoma--or cancers of the lymphatic system, which plays an integral role in the body's ability to fight infection.

27 Feb 2006

Donor age has no affect on long-term liver transplant survival

A new study on the effect of donor age on survival and recurrence of hepatitis C after liver transplantation found that it influenced short-term survival, but had no long-term effect.

22 Mar 2005

Alcohol relapse adversely affects liver transplant survival

A new study on how alcohol relapse affects survival rates after liver transplants found that it adversely affected survival rates only after 10 years. The decrease in survival rates may, however, be due to other alcohol-related diseases.

22 Mar 2005

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004